DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Employees - 18,
CEO - Mr. Dietrich John Pauls MBA,
Sector - Healthcare,
Country - US,
Market Cap - 360.78M
Altman ZScore(max is 10): 32.67, Piotroski Score(max is 10): 3, Working Capital: $46470000, Total Assets: $52524000, Retained Earnings: $-132102000, EBIT: -24110000, Total Liabilities: $4560000, Revenue: $30838000
AryaFin Target Price - $0.12 - Current Price $6.41 - Analyst Target Price $7.00
| Ticker | DMAC |
| Index | - |
| Curent Price | 6.41 |
| Change | 31.62% |
| Market Cap | 360.78M |
| Average Volume | 85.71K |
| Income | -21.71M |
| Sales | 0.00M |
| Book Value/Share | 1.12 |
| Cash/Share | 0.89 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 19 |
| Moving Avg 20days | 21.10% |
| Moving Avg 50days | 36.81% |
| Moving Avg 200days | 77.77% |
| Shares Outstanding | 42.77M |
| Earnings Date | Nov 13 AMC |
| Inst. Ownership | 13.40% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | 5.72 |
| Price/Cash | 7.19 |
| Price/FCF | - |
| Quick Ratio | 11.81 |
| Current Ratio | 11.81 |
| Debt/Equity | 0.01 |
| Return on Assets | -39.23% |
| Return on Equity | -41.90% |
| Return on Investment | -45.01% |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 69.51 |
| BETA(β) | 1.43 |
| From 52week Low | 199.53% |
| From 52week High | 11.67% |
| EPS | -0.55 |
| EPS next Year | -0.79 |
| EPS next Qtr | -0.17 |
| EPS this Year | 1.25% |
| EPS next 5 Year | 30.00% |
| EPS past 5 Year | 4.28% |
| Sales past 5 Year | -20.00% |
| EPS Y/Y | 11.24% |
| Sales Y/Y | - |
| EPS Q/Q | -24.53% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | 3.23% |
| ATR(14) | 0.43 |
| Perf Week | 19.14% |
| Perf Month | 59.45% |
| Perf Quarter | 59.85% |
| Perf Year | 140.98% |
| Perf YTD | 125.70% |
| Target Price | 7.00 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer